Springfield, MO
65808 P.O. Box 3371

417.831.6520

Nuclear Diagnosis, Inc.

16 April, 2007

U.S. Nuclear Regulatory Commission
Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4351 RE: License #24-17561-01

Dear Sir or Madam:

Please amend our license (# 24-17561-01) by adding the three physicians listed below as users under 10 CFR 35.100 and 10 CFR 35.200 (excluding xenon-133).

1) Dr. Jeffrey L. Shore, M.D. (Previously on NRC license # 24-26789-01)

2) Dr. Teodoro A. Manubay, M.D. (Previously on Arkansas Department of Health and Human Services Radioactive Material License # ARK-483-BP-10-08 and on NRC license # 24-17628-01).

3) Dr. Kenneth Mann, D.O. (Previously on NRC license #24-06806-01).

I am including a copy of each license referred to above. In addition, I am including an updated drawing of scan rooms located at one client hospital (Skaggs Community Health Center, in Branson, MO). We converted one large scan room into two smaller rooms to accommodate the addition of a third gamma camera.

I thank you in advance for your assistance.

Respectfully,

Larry D. Albaugh, CNMT
Administrative Coordinator

RECEIVED APR 2 4 2007

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 3 PAGES

MATERIALS LICENSE

Amendment No. 04

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated April 18, 2002,
1. Freeman Neosho Hospital	3. License number 24-26789-01 is renewed in its entirety to read as follows:
2. 113 West Hickory Neosho, MO 64850	4. Expiration date September 30, 2012
	5. Docket No. 030-34412 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding generators and xenon-133)	B. As needed
C. Any byproduct material identified in 10 CFR 31.11	C. Prepackaged Kits	C. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding generators and xenon-133).

C. In vitro studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 113 West Hickory, Neosho, Missouri.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 of 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-26789-01

Docket or Reference Number
030-34412

Amendment No. 04

11. Radiation Safety Officer: Jeff Shore, M.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Lowell K. Pottenger, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Paul S. Jones, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Robert L. Dever, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Jeffrey L. Shore, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
John K. Williams, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Geoffrey A. Day, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Curt A. Thompson, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 of 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-26789-01

Docket or Reference Number
030-34412

Amendment No. 04

A. Application dated April 18, 2002; and

B. Letter dated September 25, 2002.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 26 2002

By _____
Loren J. Hueter
Materials Licensing Branch
Region III

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 2 PAGES

Amendment No. 06
CORRECTED COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Twin Rivers Regional Medical Center 2. 1301 First Street Kennett, MO 63857	In accordance with letter dated March 3, 1995 3. License Number 24-17628-01 is amended in its entirety as follows: 4. Expiration Date June 31, 1998 5. Docket or Reference No. 030-13083

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding Xenon-133)	B. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding Xenon-133).

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1301 First Street, Kennett, Missouri.

11. Radiation Safety Officer: Teodoro A. Manubay, M.D.

COPY

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 2 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 24-17628-01
Docket or Reference number: 030-13083

Amendment No. 06

CORRECTED COPY

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Teodoro A. Manubay, M.D.,	for material in 10 CFR 35.100 and 35.200 (excluding Xenon-133)
James Hazel, M.D.	for material in 10 CFR 35.100 and 35.200 (excluding Xenon-133)
Parviz Massarat, M.D.	for material in 10 CFR 35.100 and 35.200 (excluding Xenon-133)

13. The licensee shall maintain records of information related to decommissioning at the location listed in Item 2. of this license as specified in 10 CFR 30.35(g) until this license is terminated by the Commission.

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 22, 1993; and

B. Letters dated March 3, 1995, and June 27, 1995.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 16 1995

By [signature]
Materials Licensing Section, Region III

COPY

ARKANSAS DEPARTMENT OF HEALTH AND HUMAN SERVICES
RADIOACTIVE MATERIAL LICENSE

Pursuant to Arkansas State Board of Health (ASBH) Regulations, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess and transfer radioactive material listed below, and to use such radioactive material for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules and regulations of the ASBH and orders of Radiation Control of the Arkansas Department of Health and Human Services, now or hereafter in effect and to any conditions specified below.

LICENSEE

1. Name: Great River Medical Center

2. Address: 1620 North Division Street
Blytheville, Arkansas 72315

3. Telephone Number: 870-762-3341

4. License Number: ARK-483-BP-10-08
Amendment Number 53

5. Expiration Date: October 1, 2008

6. Type of License: By-Product

7. Radioactive material (Element and mass number)	8. Chemical and/or physical form	9. Maximum radioactivity and/or quantity of material which licensee may possess at any one time.
A. Any radioactive material identified in RH-903, Schedule D, Group I of the ASBH Rules and Regulations for Control of Sources of Ionizing Radiation.	A. Any radiopharmaceutical identified in RH-903, Schedule D, Group I of the ASBH Rules and Regulations for Control of Sources of Ionizing Radiation.	A. As needed.
B. Any radioactive material identified in RH-903, Schedule D, Groups II and III of the ASBH Rules and Regulations for Control of Sources of Ionizing Radiation.	B. Any radiopharmaceutical identified in RH-903 Schedule D, Groups II and III of the ASBH Rules and Regulations for Control of Sources of Ionizing Radiation except generators.	B. 3 curies total.
C. Cobalt-57	C. Sealed Sources	C. 30 millicuries total. No single source to exceed 15 millicuries.
D. Iodine-131	D. Sodium Iodide (Capsule Form Only)	D. 80 millicuries total. No single capsule to exceed 30 millicuries.
E. Samarium-153	E. Lexidronam Injection (Quadramet)	E. 200 millicuries total.
F. Samarium-159	F. Sealed Source	F. 30 millicuries total.
G. Strontium-89	G. Chloride (Metastron)	G. 100 millicuries total.
H. Technetium-99m	H. DTPA	H. 100 millicuries total.

Arkansas Department of Health and Human Services
RADIOACTIVE MATERIAL LICENSE
Supplementary Sheet

License No. ARK-453-BP-10-08
Amendment Number 53

10. Authorized Use

A. Any uptake, dilution, or excretion procedure approved in RH-903, Schedule D, Group I of the ASBH Rules and Regulations for Control of Sources of Ionizing Radiation.

B. Any imaging and localization procedure approved in RH-903, Schedule D, Groups II and III of the ASBH Rules and Regulations for Control of Sources of Ionizing Radiation.

C. Calibration and reference sources.

D. For the treatment of hyperthyroidism.

E. Palliation of bone pain.

F. Calibration and reference source.

G. Palliation of bone pain.

H. To be used in a commercially available FDA-approved aerosol delivery systems for lung imaging in accordance with manufacturer's instructions in the use of the system.

CONDITIONS

11. Radioactive material may only be used at the address listed in Item 2 above.

12.A. Radioactive material shall be used by or under the supervision of:

Authorized Users	Material Authorized for Use
1. James Dunne, Jr., M.D.	Diagnostic Studies Only
2. Edgar Scott Ferguson, M.D.	All
3. Theodore A. Mamubay, M.D.	Diagnostic Studies Only
4. Jeffery Triplett, M.D.	Radiotherapeutic Pharmaceuticals Only
5. Sue Jane Valerion, D.O.	All

12.B. The Radiation Safety Officer for the activities authorized by this license is Robert Dement.

13. The licensee shall comply with the applicable provisions of Section 2, "Licensing of Radioactive Materials" and Section 3, "Standards for Protection Against Radiation", of the Arkansas State Board of Health's Rules and Regulations for Control of Sources of Ionizing Radiation.

14.A. Each sealed source containing radioactive material shall be tested for leakage and/or contamination in accordance with the requirements of Paragraph RH-1212 of the Arkansas State Board of Health's Rules and Regulations for Control of Sources of Ionizing Radiation at intervals not to exceed six (6) months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, the sealed source shall not be put into use until tested.

14.B. Each sealed source containing radioactive material possessed as a calibration or reference standard pursuant to Paragraph RH-405.c.4. shall be tested for leakage and/or contamination in accordance with Paragraph RH-405.c.5. of the Arkansas State Board of Health's Rules and Regulations for Control of Sources of Ionizing Radiation.

Arkansas Department of Health and Human Services
RADIOACTIVE MATERIAL LICENSE
Supplementary Sheet

License No. ARK-463-BP-10-08
Amendment Number 53

CONDITIONS CONTINUED

14.C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with the Department regulations. A report shall be filed within five (5) days of the test with Radiation Control, Arkansas Department of Health and Human Services, P.O. Box 1437, Slot H-30, Little Rock, Arkansas, 72203-1437, describing the equipment involved, the test results, and the corrective action taken.

14.D. Tests for leakage and/or contamination shall be performed by Paul Beck, M.S. or by other persons specifically authorized by the Department, the U.S. Nuclear Regulatory Commission, or an Agreement State to perform such services.

15. Sealed sources containing radioactive material shall not be opened or removed from their respective source holders by the licensee.

16. The licensee shall not transfer possession and/or control of materials or products containing radioactive material as a contaminant except:

A. By transfer of waste to an authorized recipient; or
B. By transfer to a specifically licensed recipient.

17. The licensee may deliver licensed material to a carrier for transport, in accordance with the provisions of Section 71.5, Title 10, Code of Federal Regulations, Part 71 "Packaging of Radioactive Material for Transport".

18. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Effected radioactive waste shall be held for decay a minimum of ten (10) half-lives.

B. Prior to disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. A record of each disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the radioactive material was placed in storage, the radionuclides disposed, the survey instrument used, the background exposure rate, the exposure rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

19. Except as otherwise specifically provided by this license, radioactive material to be administered to humans shall be procured in prepackaged, precalibrated form from a supplier who manufactures or repackages the product under appropriate pharmaceutical controls related to assay, identity, quality, purity, sterility, and non-pyrogenicity.

Arkansas Department of Health and Human Services
RADIOACTIVE MATERIAL LICENSE
Supplementary Sheet

License No. ARK-463-BP-10-08
Amendment Number 53

CONDITIONS CONTINUED

20. Biological products labeled with radionuclides or kits used to prepare such products shall be procured from a supplier licensed to manufacture and/or distribute material in accordance with a specific license issued by the U.S. Nuclear Regulatory Commission pursuant to Section 32.72 of 10 CFR Part 32, or a specific license issued by an Agreement State pursuant to equivalent regulations.

21. Technetium-99m labeled sulfur colloid preparations, which appear flocculent or aggregated, shall not be used in humans.

22. Patients containing Iodine-131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold-198 shall remain hospitalized until the residual activity is 30 millicuries or less.

23. A Quality Management Program shall be maintained in accordance with RH-1510 of the Arkansas State Board of Health's Rules and Regulations for Control of Sources of Ionizing Radiation.

24. Except as specifically provided otherwise by this license, the licensee shall possess and use radioactive material described in Items 7, 8, and 9 of this license in accordance with statements, representations, and procedures contained in the following documents:

    A. Renewal application dated January 23, 1996, signed by Randy King, Administrator/ Chief Executive Officer.

    B. Supplemental information received September 17, 2001.

    C. Supplemental information received October 24, 2001.

    D. Supplemental information received August 18, 2002.

    E. Letter dated November 2, 2004, signed by Ian Watson, CEO and Administrator, Amoris Health Systems, LLC and additional information received by facsimile on November 10, 2004.

Date August 18, 2005 By _____

Kim C. Wieback, Health Physicist
Radioactive Materials Program
Arkansas Department of Health and Human Services

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 6 PAGES

Amendment No. 74

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the facsimile dated December 15, 2004, and letter dated June 9, 2005,
1. Midwest Division - BLMC, LLC d/b/a Baptist-Lutheran Medical Center 2. 6601 Rockhill Road Kansas City, MO 64131	3. License number 24-06806-01 is amended in its entirety to read as follows: 4. Expiration date March 31, 2014 5. Docket No. 030-02343 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200		B. As needed
C. Any byproduct material permitted by 10 CFR 35.300		C. As needed (not to exceed 1 curie of I-131)
D. Cesium-137 permitted by 10 CFR 35.400	D. Sealed sources (Model [illegible] and 6503)	D. 500 millicuries
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged Kits	E. 5 millicuries
F. Gadolinium-153	F. Sealed sources (Isotopes Products Laboratories/ Dupont Pharmaceutical, Model NES-8429)	F. 4 sources not to exceed 450 millicuries each.

Authorized Use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-06906-01

Docket or Reference Number
030-02343

Amendment No. 74

C. Sealed sources need not be tested if they contain only contain not more than 100 microcuries of beta- and/or gamma-emitting material.

D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

F. Tests for leakage and/or cont[illegible], including lea[illegible]mple collection and analysis, shall be performed by persons specifica[illegible]ed by the U.[illegible]ar Regulatory Commission or an Agreement State to perform su[illegible]ces.

16. The licensee shall conduct a ph[illegible]s at other intervals approved by the U.S. Nuclear Regulatory Comm[illegible]ces and/or devices received and possessed under the license.

17. Sealed sources or detector cells co[illegible]ll not be opened or sources removed from source holders by the licensee.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number: 24-06806-01
Docket or Reference Number: 030-02343
Amendment No. 74

Kelly Rhodes-Stark, M.D.	10 CFR 35.400.
Anthony L. Wheeler, M.D.	10 CFR 35.100, 35.200, 35.300, 31.11 and Gadolinium-153 in an attenuation correction system for human radiography.
Scott Rossow, M.D.	10 CFR 35.100, 35.200, 35.300, 31.11 and Gadolinium-153 in an attenuation correction system for human radiography.
Timothy Blackburn, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures) and Gadolinium-153 in an attenuation correction system for human radiography.
James E. Sear, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures) and Gadolinium-153 in an attenuation correction system for human radiography.
Paul Becker, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures) and Gadolinium-153 in an attenuation correction system for human radiography.
Kenneth Mann, D.O.	10 CFR 35.200 and Gadolinium-153 in an attenuation correction system for human radiography.
David J. Ingle, M.D.	10 CFR 35.200, 35.300 and Gadolinium-153 in an attenuation correction system for human radiography.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14 The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-06806-01

Docket or Reference Number
030-02343

Amendment No. 74

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

E. In vitro studies.

F. Two sources for use in Elgems Ltd. Model MG ATC Rod Unit P/N ASM 000415 attenuation correction system. Two sources in a shipping container for source replacement.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 6601 Rockhill Road, Kansas City, Missouri.

11. Radiation Safety Officer: Ramesh Avva, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized for uses as indicated:

Ramesh Avva, M.D.	10 CFR 35.100, 35.200, 35.300 and Gadolinium-153 in an attenuation correction system for human radiography.
Jorge C. Paradelo, M.D.	10 CFR 35.400.
Scott C. Cozad, M.D.	10 CFR 35.400.
Jay S. Robinow, M.D.	10 CFR 35.200 and 35.400.
Michael S. Sokol, M.D.	10 CFR 35.300.
Stephen R. Smalley, M.D.	10 CFR 35.400.
Patrick W. Townsend, M.D.	10 CFR 35.400.
Bradley H. Koffman, M.D.	10 CFR 35.400.
Susan M. Smith, M.D.	10 CFR 35.400.
William Chase, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500 and Gadolinium-153 in an attenuation correction system for human radiography.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-06808-01

Docket or Reference Number
030-02343

Amendment No. 74

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 19, 2004; and

B. Letters dated February 23, 2004 and July 6, 2005.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 0 8 2005

By William P. Reichhold
William P. Reichhold
Materials Licensing Branch
Region III

Regarding NRC
license # 24-17561-01

"New Configuration"



SKAGGS COMMUNITY
HEALTH CENTER
BUSINESS 65 & SKAGGS ROAD
BRANSON, MO 65615

JWC Architecture

NUCLEAR MEDICINE
RENOVATION

FLOOR PLAN

0 1 5 10

Jan. 08, 2007
Proj. 6007

STATE OF MISSOURI
JEROME WADE
COMPTON
NUMBER
A-5687
REGISTERED ARCHITECT

1/08/07



Regarding
NRC license
24-17561-01

"Old configuration"

Nuclear Diagnosis, Inc.
P. O. Box 3371
Springfield, Missouri 65808

UNITED STATES POSTAL SERVICE
0000

AMOUNT
$1.11

U.S. POSTAGE
PAID
AURORA, MO
65605
APR 17 '07
00077611-02
60532

United States Nuclear Regulatory
Commission
Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4352

FIRST CLASS